Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jun 21;2016(6):CD010696.
doi: 10.1002/14651858.CD010696.pub2.

Betahistine for symptoms of vertigo

Louisa Murdin  1 , Kiran Hussain, Anne G M Schilder
Affiliations
Meta-Analysis

Betahistine for symptoms of vertigo

Louisa Murdin et al. Cochrane Database Syst Rev. .

Abstract

Background: Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes.

Objectives: To assess the effects of betahistine in patients with symptoms of vertigo from different causes.

Search methods: The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. We also contacted manufacturers and researchers in the field. The date of the search was 21 September 2015.

Selection criteria: We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings.

Data collection and analysis: We used the standard methodological procedures expected by Cochrane. Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).

Main results: We included 17 studies, with a total of 1025 participants; 12 studies were published (567 patients) and five were unpublished (458 patients). Sixteen studies including 953 people compared betahistine with placebo. All studies with analysable data lasted three months or less. The majority were at high risk of bias, but in some the risk of bias was unclear. One study, at high risk of bias, included 72 people with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also had particle repositioning manoeuvres. The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of time it was taken for, the study methods and the way any improvement in vertigo symptoms was measured. Using the GRADE system, we judged the quality of evidence overall to be low for two outcomes (proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group: risk ratio (RR) 1.30, 95% confidence interval (CI) 1.05 to 1.60; 606 participants; 11 studies). This result should be interpreted with caution as the test for statistical heterogeneity as measured by the I(2) value was high.Adverse effects (mostly gastrointestinal symptoms and headache) were common but medically serious events in the study were rare and isolated: there was no difference in the frequency of adverse effects between the betahistine and placebo groups, where the rates were 16% and 15% respectively (weighted values, RR 1.03, 95% CI 0.76 to 1.40; 819 participants; 12 studies).Sixteen per cent of patients from both the betahistine and the placebo groups withdrew (dropped out) from the studies (RR 0.96, 95% CI 0.65 to 1.42; 481 participants; eight studies).Three studies looked at objective vestibular function tests as an outcome; the numbers of participants were small, techniques of measurement very diverse and reporting details sparse, so analysis of this outcome was inconclusive.We looked for information on generic quality of life and falls, but none of the studies reported on these outcomes.

Authors' conclusions: Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms. Betahistine is generally well tolerated with a low risk of adverse events. Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families.

PubMed Disclaimer

Conflict of interest statement

Louisa Murdin has no interests to declare.

Kiran Hussain has no interests to declare.

Anne Schilder is joint Co‐ordinating Editor of Cochrane ENT, but had no role in the editorial process for this review. Her evidENT team at UCL is supported by her NIHR Research Professorship award with the remit to develop a UK infrastructure and programme of clinical research in ENT, Hearing and Balance. Her institution has received a grant from GSK for a study on the microbiology of acute tympanostomy tube otorrhoea.

Update of

  • doi: 10.1002/14651858.CD010696

References

References to studies included in this review

Burkin 1967 {published data only}
    1. Burkin A. Betahistine treatment for Meniere's syndrome. Clinical Medicine 1967;74:41-8.
Canty 1981 {published data only}
    1. Canty P, Valentine J. Betahistine in peripheral vertigo: a double-blind, placebo-controlled, cross-over study of Serc versus placebo. Journal of Laryngology and Otology 1981;95:687-92. - PubMed
Conraux 1988 {published data only}
    1. Conraux C, Cellier D. Chronic vertigo sensations. Multi-centre randomised double-blind comparative study 8mg Serc vs placebo in patients suffering from chronic vertigo [Les sensations vertigineuses chroniques: efficacité de la betahistine prouvée dans un essai therapeutique en double aveugle]. Impact Medecin 1988;260:63-5.
Duphar 77054 1983 {unpublished data only}
    1. Duphar. 77054 Betahistine dihydrochloride and peripheral vertigo: a double blind placebo-controlled trial in outpatients. Unpublished data 1983.
Duphar H10800580M 1984 {unpublished data only}
    1. Duphar. H10800580M A prospectively randomised placebo controlled double blind parallel group study of betahistine dihydrochloride in patients presenting with vertigo and central signs on electronystagmography. Unpublished data 1984.
Duphar H10802786F/M 1989 {unpublished data only}
    1. Duphar. H10802786F/M Double blind randomised multicentre study to compare Serc 8mg with placebo. Unpublished data 1989.
Duphar H10803592F 1997 {unpublished data only}
    1. Duphar. H10803592F Double blind multicentre randomised comparative study of Serc 24mg vs placebo in two groups of patients with recurrent vertigo. Unpublished data 1997.
Duphar H108906NL 1990 {unpublished data only}
    1. Duphar. H 108.906 A double blind placebo-controlled study with betahistine (Betaserc) in forms of vertigo eligible for drug treatment. Unpublished data 1990.
Fischer 1985 {published data only}
    1. Fischer AJ, Van Elferen LWM. Betahistine in the treatment of paroxysmal attacks of vertigo. A double blind investigation [Betahistine bij de behandeling van aanyalsgewijs optredende duizeligheid. Een dubbelblind onderzoek]. JDR (J Drug Therapy Res) 1985;10:933-7.
Guneri 2012 {published data only}
    1. Guneri EA, Kustutan O. The effects of betahistine in addition to Epley maneuver in posterior canal benign paroxysmal positional vertigo. Otolaryngology - Head and Neck Surgery 2012;146(1):104-8. - PubMed
Legent 1988 {published data only}
    1. Legent F, Calais C, Cellier D. Trial of betahistine in paroxysmal vertigo [French]. Concours Medical 1988;110(29):2539-43.
Mira 2003 {published data only}
    1. Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. European Archives of Oto-Rhino-Laryngology 2003;260(2):73-7. - PubMed
Okamoto 1968 {published data only}
    1. Okamoto K, Hazeyama F, Taira T, Yoshida A, Onoda T. Therapeutic results of betahistine on Meniere's disease. Multi-variable analysis of the results of the double blind test and Fisher's evaluation method. Iryo 1968;22(5):650-66. - PubMed
Oosterveld 1989 {published data only}
    1. Oosterveld WJ, Blijleven W, Elferen LWM. Betahistine versus placebo in paroxysmal vertigo; a double blind trial. Tijdschr Ther Geneesm Onderz 1989;14:122-6.
Otto 2008 {published data only}
    1. Otto V, Fischer B, Schwarz M, Baumann W, Preibisch-Effenberger R. Treatment of vertebrobasilar insufficiency--associated vertigo with a fixed combination of cinnarizine and dimenhydrinate. International Tinnitus Journal 2008;14(1):57-67. - PubMed
Ricci 1987 {published data only}
    1. Ricci V, Sittoni V, Nicora M. Efficacy and safety of betahistine hydrochloride versus placebo in Meniere's disease [Valutazione terapeutica e tollerabilita del cloridrato di betaistina (microser) in confronto a placebo nella malattia di meniere]. Rivista Italiana di Ornitologia Audiologia e Foniatria 1987;7(3):347-50.
Salami 1984 {published data only}
    1. Salami A, Delle PM, Tinelli E, Jankowska B. Double blind study between betahistine hydrochloride and placebo in the treatment of Meniere's syndromes [Studio a doppia cecita tra cloridrato di betaistina e placebo nel trattamento delle sindromi menieriformi]. Il Valsalva 1984;60:302-12.

References to studies excluded from this review

Bertrand 1972 {published data only}
    1. Bertrand RA. Méniére's disease: subjective and objective evaluation of medical treatment with betahistine HCl. Acta Oto-Laryngologica. Supplement 1972;305:48-69. - PubMed
Elia 1966 {published data only}
    1. Elia JC. Double-blind evaluation of a new treatment for Meniere's syndrome. JAMA 1966;196:187-9. - PubMed
Frew 1976 {published data only}
    1. Frew IJ, Menon GN. Betahistine hydrochloride in Méniére's disease. Postgraduate Medical Journal 1976;52(610):501-3. - PMC - PubMed
Hommes 1972 {published data only}
    1. Hommes OR. A study of the efficacy of betahistine in Méniére's syndrome. Acta Oto-Laryngologica. Supplement 1972;305:70-9. - PubMed
Meyer 1985 {published data only}
    1. Meyer ED. Treatment of Meniere disease with betahistine dimesilate (Aequamen)--double-blind study versus placebo (crossover). Laryngologie, Rhinologie, Otologie 1985;64(5):269-72. - PubMed
NCT00160238 {published data only}
    1. Solvay Pharmaceuticals. A double-blind, placebo-controlled, randomized, clinical study of the effects of Betaserc® 24 mg (1 tablet b.i.d over 3 months) on vestibular compensation following vestibular neurotomy in patients with disabling Meniere's disease [completed]. http://clinicaltrials.gov/show/NCT00160238 2008.
NCT00474409 {published data only}
    1. NCT00474409. A multicenter, placebo-controlled, double-blind study to evaluate the efficacy and safety of betahistine mesilate in the treatment of patients with vertigo caused by cerebral infarction in posterior circulation. http://clinicaltrials.gov/show/NCT00474409 2007 (accessed 5 August 2013).
Oosterveld 1984 {published data only}
    1. Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. Journal of Laryngology and Otology 1984;98(1):37-41. - PubMed
Purohit 1988 {published data only}
    1. Purohit SD, Jain DK, Agarwal S, Gupta ML, Sharma TN, Jain NK, et al. Betahistine dihydrochloride in the management of streptomycin induced vestibular damage (assessed by craniocorpography). Lung India 1988;6(2):61-4.
Redon 2011 {published data only}
    1. Redon C, Lopez C, Bernard-Demanze L, Dumitrescu M, Magnan J, Lacour M, et al. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. Journal of Clinical Pharmacology 2011;51(4):538-48. - PubMed
Schmidt 1992 {published data only}
    1. Schmidt JT, Huizing EH. The clinical drug trial in Meniere's disease with emphasis on the effect of betahistine SR. Acta Oto-Laryngologica. Supplement 1992;497:1-189. - PubMed
Singarelli 1979 {published data only}
    1. Singarelli S. Double-blind trial on the efficacy of betahistine hydrochloride in a group of outpatients with positional vertigo and tinnitus. Nuovo Archivio Italiano di Otologia Rinologia e Laringologia 1979;Suppl 7:69-72.
Verspeelt 1996 {published data only}
    1. Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. European Journal of Clinical Pharmacology 1996;51:15-22. - PubMed
Watanabe 1967 {published data only}
    1. Watanabe K, Fukami J, Yoshimoto H, Ueda M, Suzuki J. Evaluation of the effect of betahistine in Meniere's disease by double-blind test and multivariate analysis. Jibiinkoka 1967;39(11):1237-50. - PubMed
Wilmot 1976 {published data only}
    1. Wilmot TJ, Menon GN. Betahistine in Meniere's disease. Journal of Laryngology and Otology 1976;90:833-40. - PubMed

References to ongoing studies

BEMED {published data only}
    1. Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial - BETAVEST. EUCTR. Available from: http://apps.who.int/trialsearch/trial.aspx?trialid=EUCTR2009-013702-14-DE 2010 (accessed 5 August 2013). [EUCTR2009-013702-14-DE]
BETAVEST {published data only}
    1. Medical treatment of Meniere's disease with betahistine: a placebo-controlled, dose-finding study. ISRCTN 2007 (accessed 5 August 2013). [http://www.controlled-trials.com/ISRCTN44359668/]

Additional references

AAO‐HNS 1995
    1. AAO-HNS. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease, American Academy of Otolaryngology - Head and Neck Foundation. Otolaryngology - Head and Neck Surgery 1995;113:181-5. - PubMed
Adrion 2016
    1. Adrion C, Fischer C S, Wagner J, Gurkov R, Mansmann U, Strupp M. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016;352:h6816. - PMC - PubMed
Agus 2013
    1. Agus S, Benecke H, Thum C, Strupp M. Clinical and demographic features of vertigo: findings from the REVERT registry. Frontiers in Neurology 2013;4:48. - PMC - PubMed
Barak 2008
    1. Barak N. Betahistine: what's new on the agenda? Expert Opinion on Investigational Drugs 2008;17:795-804. - PubMed
Bisdorff 2009
    1. Bisdorff A, Von Brevern M, Lempert T, Newman-Toker DE. Classification of vestibular symptoms: towards an international classification of vestibular disorders. Journal of Vestibular Research: Equilibrium & Orientation 2009;19:1-13. - PubMed
Cohen 2000
    1. Cohen HS, Kimball KT. Development of the vestibular disorders activities of daily living scale. Archives of Otolaryngology--Head & Neck Surgery 2000;126:881-7. - PubMed
Della Pepa 2006
    1. Della Pepa C, Guidetti G, Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngologica Italica 2006;26:208-15. - PMC - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. - PMC - PubMed
Handbook 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hannaford 2005
    1. Hannaford PC, Simpson JA, Bisset AF, Davis A, McKerrow W, Mills R. The prevalence of ear, nose and throat problems in the community: results from a national cross-sectional postal survey in Scotland. Family Practice 2005;22:227-33. - PubMed
Hilton 2014
    1. Hilton M, Pinder D. The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No: CD003162. [DOI: 10.1002/14651858.CD003162.pub3] - DOI - PMC - PubMed
Hunt 2012
    1. Hunt WT, Zimmermann EF, Hilton MP. Modifications of the Epley (canalith repositioning) manoeuvre for posterior canal benign paroxysmal positional vertigo (BPPV). Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No: CD008675. [DOI: 10.1002/14651858.CD008675.pub2] - DOI - PMC - PubMed
Ihler 2012
    1. Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS One 2012;7:e39086. - PMC - PubMed
Jacobson 1990
    1. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Archives of Otolaryngology--Head and Neck Surgery 1990;116:424-7. - PubMed
James 2001
    1. James A, Burton MJ. Betahistine for Ménière's disease or syndrome. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No: CD001873. [DOI: 10.1002/14651858.CD001873] - DOI - PMC - PubMed
Karatas 2010
    1. Karatas M. Vascular vertigo: epidemiology and clinical syndromes. Neurologist 2010;17:1-10. - PubMed
Kruschinski 2008
    1. Kruschinski C, Kersting M, Breull A, Kochen MM, Koschack J, Hummers-Pradier E. Frequency of dizziness-related diagnoses and prescriptions in a general practice database. Zeitschrift fur Evidenz Fortbildung und Qualitat im Gesundheitswesen 2008;102:313-9. - PubMed
Lempert 2012
    1. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, et al. Vestibular migraine: diagnostic criteria. Journal of Vestibular Research: Equilibrium & Orientation 2012;22:167-72. - PubMed
Linde 2004
    1. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No: CD003225. [DOI: 10.1002/14651858.CD003225.pub2] - DOI - PubMed
Lopez‐Escamez 2015
    1. Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, et al. Diagnostic criteria for Meniere's disease. Journal of Vestibular Research 2015;25(1):1-7. - PubMed
Martinez 1972
    1. Martinez DM. The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. Acta Oto-Laryngologica. Supplement 1972;305:29-47. - PubMed
McDonnell 2015
    1. McDonnell MN, Hillier SL. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No: CD005397. [DOI: 10.1002/14651858.CD005397.pub4] - DOI - PMC - PubMed
Megnigbeto 2001
    1. Megnigbeto CA, Sauvage JP, Launois R. The European Evaluation of Vertigo (EEV) scale: a clinical validation study. Revue de Laryngologie - Otologie - Rhinologie 2001;122:95-102. - PubMed
Murdin 2015
    1. Murdin L, Schilder AG. Epidemiology of balance symptoms and disorders in the community: a systematic review. Otology & Neurotology 2015;36(3):387-92. [DOI: 10.1097/MAO.0000000000000691] - DOI - PubMed
Nauta 2014
    1. Nauta JJ. Meta-analysis of clinical studies with betahistine in Meniere's disease and vestibular vertigo. European Archives of Oto-Rhino-Laryngology 2014;271(5):887-97. - PubMed
Nazareth 1999
    1. Nazareth I, Yardley L, Owen N, Luxon L. Outcome of symptoms of dizziness in a general practice community sample. Family Practice 1999;16:616-8. - PubMed
Neuhauser 2005
    1. Neuhauser HK, Brevern M, Radtke A, Lezius F, Feldmann M, Ziese T, et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology 2005;65:898-904. - PubMed
Newman‐Toker 2008
    1. Newman-Toker DE, Dy FJ, Stanton VA, Zee DS, Calkins H, Robinson KA. How often is dizziness from primary cardiovascular disease true vertigo? A systematic review. Journal of General Internal Medicine 2008;23:2087. - PMC - PubMed
Pathy 1977
    1. Pathy J, Menon G, Reynolds A, Van Strik R. Betahistine hydrochloride (Serc) in cerebrovascular disease a placebo-controlled study. Age and Ageing 1977;6(3):179-84. - PubMed
Ramos 2015
    1. Ramos Alcocer R, Ledezma Rodríguez JG, Navas Romero A, Cardenas Nuñez JL, Rodríguez Montoya V, Deschamps JJ, et al. Use of betahistine in the treatment of peripheral vertigo. Acta Oto-Laryngologica 2015 Aug 6 [Epub ahead of print]. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Strupp 2013
    1. Strupp M, Brandt T. Peripheral vestibular disorders. Current Opinion in Neurology 2013;26:81-9. - PubMed
Timmerman 1994
    1. Timmerman H. Pharmacotherapy of vertigo - any news to be expected? Acta Oto-Laryngologica 1994;513:28-32. - PubMed
Wiltink 2009
    1. Wiltink J, Tschan R, Michal M, Subic-Wrana C, Eckhardt-Henn A, Dieterich M, et al. Dizziness: anxiety, health care utilization and health behavior--results from a representative German community survey. Journal of Psychosomatic Research 2009;66:417-24. - PubMed
Yardley 1998
    1. Yardley L, Owen N, Nazareth I, Luxon L. Prevalence and presentation of dizziness in a general practice community sample of working age people. British Journal of General Practice 1998;48:1131-5. - PMC - PubMed

References to other published versions of this review

Murdin 2013
    1. Murdin L, Hussain K, Schilder AGM. Betahistine for symptoms of vertigo. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No: CD010696. [DOI: 10.1002/14651858.CD010696] - DOI - PMC - PubMed

Publication types

MeSH terms